Company News 

Seven Days: 22 May 2020

Seven Days: 22 May 2020

Vaccine hopes

More data needed

Moderna (US:MRNA) said this week that it had seen positive results from its early-stage coronavirus vaccine trials. The US biotech group’s vaccine candidate “elicited neutralising antibodies” in eight participants – triggering an immune response like that brought about by a natural infection. Shares in Moderna soared by more than a fifth in response. Hours later, Moderna announced a $1.34bn (£1.1bn) share sale to fund the manufacturing of its vaccine candidate. But the group’s shares stumbled the following day, after Stat News reported that experts had questioned the lack of critical information in Moderna’s update.

To continue reading, subscribe today

and enjoy unlimited access to the following:

  • Tips of the Week
  • Funds coverage
  • Weekly features on big investment themes
  • Trading ideas
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now